Philogen licenses autoimmune disease drug to Pfizer

01/4/2013 | Reuters

Pfizer secured exclusive, worldwide rights to develop and market Philogen's Dekavil, an investigational drug for autoimmune diseases. Dekavil is an early-stage antibody that targets inflammatory disease sites. The deal entitles Philogen to an an upfront fee and potential milestone fees and royalties.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI